Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma

Oncology Letters

Volumn 3, Issue 5, 2012, Pages 1002-1006

  Fujiwara, Hiroyuki ^a   Jobo, Toshiko ^b,c   Takei, Yuji ^a   Saga, Yasushi ^a   Imai, Manami ^b   Arai, Tsutomu ^b   Taneichi, Akiyo ^a   Machida, Shizuo ^a   Takahashi, Yoshifumi ^a   Suzuki, Mitsuaki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Social Insurance Sagamino Hospital   (Japan)

Author keywords

Endometrial carcinoma; Fertility sparing treatment; Medroxyprogesterone acetate

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; FEMALE; FERTILITY SPARING TREATMENT; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREMENOPAUSE; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 84863252817     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.602     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005.
3. Parazzini F, La Vecchia C, Bocciolone L and Franceschi S: The epidemiology of endometrial cancer. Gynecol Oncol 41: 1-16, 1991.
4. Brinton LA, Berman ML, Mortel R, et al: Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167: 1317-1325, 1992.
5. Lurain JR: Uterine Cancer. In: Berek & Novak's Gynecology, Berek JS (ed). 14th edition. Lippincott Williams & Wilkins, Philadelphia, pp.1343-1401, 2007.
6. Crissman JD, Azoury RS, Barnes AE and Schellhas HF: Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 57: 699-704, 1981.
7. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T, Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 41: 139-147, 2011.
8. Gadducci A, Spirito N, Baroni E, Tana R and Genazzani AR: The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol 25: 683-691, 2009.
9. Kim YB, Holschneider CH, Ghosh K, Nieberg RK and Montz FJ: Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79: 320-327, 1997.
10. Randall TC and Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90: 434-440, 1997.
11. Imai M, Jobo T, Sato R, Kawaguchi M and Kuramoto H: Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol 22: 217-220, 2001.
12. Kaku T, Yoshikawa H, Tsuda H, et al: Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 167: 39-48, 2001.
13. Wang CB, Wang CJ, Huang HJ, et al: Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 94: 2192-2198, 2002.
14. Niwa K, Tagami K, Lian Z, Onogi K, Mori H and Tamaya T: Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 112: 317-320, 2005.
15. Ushijima K, Yahata H, Yoshikawa H, et al: Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25: 2798-2803, 2007.
16. Yamazawa K, Hirai M, Fujito A, et al: Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22: 1953-1958, 2007.
17. Hahn HS, Yoon SG, Hong JS, et al: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 19: 1068-1073, 2009.
18. Gotlieb WH, Beiner ME, Shalmon B, et al: Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 102: 718-725, 2003.
19. Mitsushita J, Toki T, Kato K, Fujii S and Konishi I: Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate. Gynecol Oncol 79: 129-132, 2000.
20. Kinkel K: Pitfalls in staging uterine neoplasm with imaging: a review. Abdom Imaging 31: 164-173, 2006.
21. Ota T, Yoshida M, Kimura M and Kinoshita K: Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15: 657-662, 2005.
22. Thigpen JT, Brady MF, Alvarez RD, et al: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736-1744, 1999.
23. Kothari R, Seamon L, Cohn D, Fowler J and O'Malley DM: Stage IV endometrial cancer after failed conservative management: a case report. Gynecol Oncol 111: 579-582, 2008.
24. Zivanovic O, Carter J, Kauff ND and Barakat RR: A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115: 504-509, 2009.
25. Fujiwara H, Ogawa S, Motoyama M, et al: Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women: a report of six cases. Hum Reprod 24: 1045-1050, 2009.